On the morning of December 12, 2016, China Resources Pharmaceutical Group Co., Ltd. (hereinafter: CR Pharma) and WuXi AppTec(Shanghai) Co., Ltd (hereinafter: WuXi AppTec) formally signed the agreement on the cooperation in co-development of innovative drugs targeting respiratory and blood diseases at Beijing.Chronic obstructive pulmonary diseases (COPD), pulmonary fibrosis and thrombotic disease are high incidence and frequently-occurring diseases in a global context, which leads a strong market demand. At the time of signing the agreement, both parties have obtained several promising candidates with novel pharmacological mechanism of action. All of these compounds have been filed for worldwide patent protection.CR Pharma was the second largest pharmaceutical manufacturer and pharmaceutical distributor in China. WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform company with global operations. CR Pharma believes the cooperation with WuXi AppTec enables both parties to realize their respective advantages, and will strengthen CR Pharma’s research capacity and optimize its innovative drug line in strategic therapeutic areas.
